English | 繁體

Search in the results

UM

Browse/Search Results:  1-9 of 9 Help

Selected(0)Clear Items/Page:    Sort:
Emerging anticancer potential and mechanisms of snake venom toxins: A review Journal article
Guo, Xijun, Fu, Yuanfeng, Peng, Junbo, Fu, Ying, Dong, Shuai, Ding, Ren Bo, Qi, Xingzhu, Bao, Jiaolin. Emerging anticancer potential and mechanisms of snake venom toxins: A review[J]. International Journal of Biological Macromolecules, 2024, 269.
Authors:  Guo, Xijun;  Fu, Yuanfeng;  Peng, Junbo;  Fu, Ying;  Dong, Shuai; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:7.7/7.7 | Submit date：2024/07/04
Angiogenesis  Anticancer  Cell proliferation  Invasion and migration  Programmed cell death  Snake venom toxins  
Emerging anticancer potential and mechanisms of snake venom toxins: A review Review article
2024
Authors:  Guo, Xijun;  Fu, Yuanfeng;  Peng, Junbo;  Fu, Ying;  Dong, Shuai; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:7.7/7.7 | Submit date：2024/05/16
Angiogenesis  Anticancer  Cell Proliferation  Invasion And Migration  Programmed Cell Death  Snake Venom Toxins  
Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors Journal article
Zou, Huimin, Ge, Ying, Chen, Wenge, Yao, Dongning, Oi Lam Ung, Carolina, Lai, Yunfeng, Hu, Hao. Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors[J]. International Immunopharmacology, 2024, 132, 111947.
Authors:  Zou, Huimin;  Ge, Ying;  Chen, Wenge;  Yao, Dongning;  Oi Lam Ung, Carolina; et al.
Favorite | TC[WOS]:0 TC[Scopus]:1  IF:4.8/5.0 | Submit date：2024/05/16
Camrelizumab  China  Hepatocellular Carcinoma  Programmed Cell Death Protein-1 Inhibitor  Tislelizumab  
An analgesic peptide H-20 attenuates chronic pain via the PD-1 pathway with few adverse effects Journal article
Zhao, Long, Luo, Hao, Ma, Yu, Zhu, Shengze, Wu, Yongjiang, Lu, Muxing, Yao, Xiaojun, Liu, Xin, Chen, Gang. An analgesic peptide H-20 attenuates chronic pain via the PD-1 pathway with few adverse effects[J]. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119(31).
Authors:  Zhao, Long;  Luo, Hao;  Ma, Yu;  Zhu, Shengze;  Wu, Yongjiang; et al.
Favorite | TC[WOS]:10 TC[Scopus]:11  IF:9.4/10.8 | Submit date：2023/01/30
Analgesic  Chronic Pain  Dorsal Root Ganglion  Programmed Cell Death Protein 1  Src Homology 2 Domain–containing Tyrosine Phosphatase 1  
Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes Journal article
Haotian Liao, Wen Chen, Yunlu Dai, Joseph J. Richardson, Junling Guo, Kefei Yuan, Yong Zeng, Kunlin Xie. Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes[J]. FRONTIERS IN ONCOLOGY, 2019, 9.
Authors:  Haotian Liao;  Wen Chen;  Yunlu Dai;  Joseph J. Richardson;  Junling Guo; et al.
Favorite | TC[WOS]:32 TC[Scopus]:32  IF:3.5/4.0 | Submit date：2020/05/12
Programmed Cell Death-ligands  Macrophage  Tumor Immune Stroma  Tumor Microenvironment  Antipd-1 Axis Therapy  Hepatocellular Carcinoma  
Targeting PD-L1 Protein: Translation, Modification and Transport Journal article
Wei R., Guo L., Wang Q., Miao J., Kwok H.F., Lin Y.. Targeting PD-L1 Protein: Translation, Modification and Transport[J]. Current protein & peptide science, 2019, 20(1), 82-91.
Authors:  Wei R.;  Guo L.;  Wang Q.;  Miao J.;  Kwok H.F.; et al.
Favorite | TC[WOS]:22 TC[Scopus]:22  IF:1.9/3.0 | Submit date：2018/12/19
Immunotherapy  Modification  Programmed Cell Death Protein 1 (Pd-1)  Programmed Death Ligand 1 (Pd-l1)  Translation  Transport.  
Global patent landscape of programmed cell death 1: implications of the rapid expansion Journal article
Kong, Xiangjun, Zhang, Qianru, Lai, Yunfeng, Hu, Hao, Chen, Xin, Hu, Yuanjia. Global patent landscape of programmed cell death 1: implications of the rapid expansion[J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2018, 28(1), 69-80.
Authors:  Kong, Xiangjun;  Zhang, Qianru;  Lai, Yunfeng;  Hu, Hao;  Chen, Xin; et al.
Favorite | TC[WOS]:4 TC[Scopus]:4  IF:5.4/6.4 | Submit date：2018/10/30
Programmed Cell Death 1 (Pd-1)  Patent Landscape  Patent Citation Network  Co-patent  Technology Flow  Immunotherapy  
An alternative splice form of CMTM8 induces apoptosis Journal article
Li D., Jin C., Yin C., Zhang Y., Pang B., Tian L., Han W., Ma D., Wang Y.. An alternative splice form of CMTM8 induces apoptosis[J]. International Journal of Biochemistry and Cell Biology, 2007, 39(11), 2107-2119.
Authors:  Li D.;  Jin C.;  Yin C.;  Zhang Y.;  Pang B.; et al.
Favorite | TC[WOS]:20 TC[Scopus]:21 | Submit date：2019/01/16
Chemokine-like Factor (Cklf)-like Marvel Transmembrane Domain Containing 8  Chemokine-like Factor (Cklf)-like Marvel Transmembrane Domain Containing 8-v2  Programmed Cell Death  
The 5′-upstream region of human programmed cell death 5 gene contains a highly active TATA-less promoter that is up-regulated by etoposide Journal article
Xu M., Cheng N., Gui L., Lai M., Wang Y., Xia D., Rui M., Zhang Y., Ma D.. The 5′-upstream region of human programmed cell death 5 gene contains a highly active TATA-less promoter that is up-regulated by etoposide[J]. Gene, 2004, 329(1-2), 39-49.
Authors:  Xu M.;  Cheng N.;  Gui L.;  Lai M.;  Wang Y.; et al.
Favorite | TC[WOS]:7 TC[Scopus]:7 | Submit date：2019/01/16
5′-upstream Region  Apoptosis  Etoposide  Kb  Kilobase(s)  Pdcd5  Phenylmethylsulfonyl Fluoride  Pmsf  Programmed Cell Death 5  Reverse Transcription  Rt